BIAF stock news · bioAffinity Technologies, Inc.
Get alerts for BIAF
Follow bioAffinity Technologies, Inc. (BIAF) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BIAFbioAffinity Technologies, Inc. will sponsor a talk at CHEST 2026 about its CyPath Lung® product and new asthma research.
NeutralBIAF plans to discuss its lung tests and positive research at CHEST 2026. The filing reports no specific results or sales, so it does not change the company's outlook.
bioAffinity Technologies, Inc. says it will share new findings on lung tests at CHEST 2026.
NeutralbioAffinity plans to present new test data at CHEST 2026, but the tests remain unvalidated and unavailable for diagnosis. The announcement does not yet show a change in the company's business prospects.
bioAffinity Technologies, Inc. got a green light from Japan for a patent on its CyPath® Lung test.
Good for BIAFThe Japan Patent Office intends to grant bioAffinity a patent for a lung cancer prediction method tied to its CyPath Lung test. That may strengthen its protection in Japan.
bioAffinity Technologies, Inc. shares news about important happenings.
Good for BIAFBIAF said CyPath Lung sales rose by more than 100% through Q3 2026 versus 2025, pointing to stronger use of its test despite no sales-dollar or profit figures.
bioAffinity Technologies, Inc. shared news about delivering its CyPath® Lung product to more than 300 doctors at a conference.
NeutralBIAF presented its CyPath Lung test to more than 300 health professionals and VA leaders. No sales or patient use were reported, so this does not change its outlook.
bioAffinity Technologies, Inc. will show two posters about its CyPath® Lung test at the 2026 NAVREF Annual Conference.
NeutralbioAffinity filed an 8-K saying it will present two posters on CyPath Lung at NAVREF. This is neutral because no new data or approvals were reported.
On Friday, 12 health care stocks changed a lot in price, with IM Cannabis jumping 246%.
Good for BIAFbioAffinity Technologies shares increased 15.2% to $10.08. The intraday rise indicates stronger investor demand for the stock today.
On Thursday, 12 health care stocks changed a lot, with Aethlon Medical jumping 330.8% and Longeveron dropping 57.3%.
NeutralbioAffinity's shares rose sharply in the session, yet the article only reports the price move and a small market value, leaving company prospects unchanged.
bioAffinity Technologies, Inc. shared important information with the SEC about an upcoming investment conference.
NeutralbioAffinity filed an 8-K to furnish presentation slides for the H.C. Wainwright conference; the filing gives no financial updates, so the news is neutral for the company.
On Tuesday, 12 health care stocks saw big price changes during the day.
Bad for BIAFbioAffinity Technologies declined 33.98% to $10.08, reflecting a strong negative market reaction that hurts sentiment.
Thursday's intraday session sees significant fluctuations in 12 health care stocks.
Good for BIAFShares rose sharply (22.87%), a clear positive intraday market reaction.